石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for Carbidopa and Levodopa Sustained-release Tablets (Carbidopa 50mg, Levodopa 200mg) and Dapagliflozin Tablets (10mg and 5mg) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation, with Carbidopa and Levodopa Sustained-release Tablets being the first of such approval for the PRC entities.

Carbidopa and Levodopa Sustained-release Tablet is mainly used in the treatment of primary Parkinson's disease, post-encephalitic Parkinson's syndrome, symptomatic Parkinson's syndrome (carbon monoxide or manganese poisoning), and for patients with end-of-dose or dyskinesias phenomenon who have previously been treated with levodopa in compound preparation with decarboxylase inhibitor or as monotherapy. Dapagliflozin Tablet is mainly used in adult patients with type 2 diabetes and adult patients with heart failure. As stated in the Company's announcement dated 25 March 2024, the Group's Dapagliflozin bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

The Board is also pleased to announce that the Group has obtained the approvals for drug production and registration for Etomidate Medium and Long Chain Fat Emulsion Injection (10ml:20mg) and Isosorbide Dinitrate Injection (10ml:10mg) from the NMPA, both being under type 4 chemical drug and regarded as passing the consistency evaluation, with Etomidate Medium and Long Chain Fat Emulsion Injection being the third of such approvals for the PRC entities.

Etomidate Medium and Long Chain Fat Emulsion Injection is mainly used for the induction of general anesthesia. As stated in the Company's announcement dated 23 June 2024, the Group's Etomidate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Isosorbide Dinitrate Injection is mainly used in the treatment of acute myocardial infarction, acute left heart failure, and in combination with standard therapy for the symptomatic treatment of unstable angina and the long-term treatment of vasospastic angina.

In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Isoprenaline Hydrochloride Injection (1ml:0.2mg) from the NMPA, being under type 3 chemical drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. Isoprenaline Hydrochloride Injection is mainly used in the treatment of cardiogenic or septic shock, complete atrioventricular block and sudden cardiac arrest. As stated in the Company's announcement dated 31 January 2024, the Group's Isoprenaline hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 5 July 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.